Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis
- PMID: 19365595
- DOI: 10.1007/s00415-009-0120-2
Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis
Abstract
Background: Multiple sclerosis has a variable disease course. The contribution of modifiable lifestyle factors to disease course has not been well studied, although one cohort has reported that smoking is associated with conversion to secondary progressive MS course and another that smoking is not.
Methods: We conducted a prospective cohort study of people with MS in Southern Tasmania from 2002 to 2004 with 78% (203/259) of eligible participating and 198 with one or more reviews and confirmed MS. The cohort had a high retention rate (90% (183/203)). The median follow-up time was 909 days. Smoking data were collected at baseline and six-monthly reviews. Clinical disability assessments were conducted annually in conjunction with a real time clinical notification system for relapses. A repeated measures analysis and other statistical methods were used.
Results: Cumulative pack-years (p-y) smoked after cohort entry was associated with an increase in longitudinal MSSS (p < 0.001). Relative to the 0 pack years (p-y) category (in the year prior to the MSSS measure) those in the 0 to 1 p-y category had an adjusted mean difference in MSSS of 0.34 (95% CI 0.28, 0.66); those in the 1 to 2 p-y category had a 0.41 (95% CI -0.03, 0.85) increase; and those in the 2 or more p-y category had a 0.99 (95% CI 0.41, 1.58) increase in MSSS. Similar results were found using a variety of statistical approaches or EDSS as a clinical outcome. Smoking during the cohort period was not associated with relapse (cumulative pack years smoked after cohort entry, HR 0.94 (0.69, 1.26) per pack year).
Conclusion: A better understanding of the mechanisms underlying smoking and multiple sclerosis, particularly progressive forms of the disease, may provide new insights for the eventual goal of better treatment and prevention of multiple sclerosis.
Similar articles
-
Assessing disability progression using the WHODAS 2.0 in multiple sclerosis: Investigating clinical and socio-demographic factors in a large longitudinal cohort study (TONiC-MS).Mult Scler Relat Disord. 2025 Jan;93:106228. doi: 10.1016/j.msard.2024.106228. Epub 2024 Dec 10. Mult Scler Relat Disord. 2025. PMID: 39706109
-
Pediatric Multiple Sclerosis Severity Score in a large US cohort.Neurology. 2020 Sep 29;95(13):e1844-e1853. doi: 10.1212/WNL.0000000000010414. Epub 2020 Jul 20. Neurology. 2020. PMID: 32690790 Free PMC article.
-
Natural history of multiple sclerosis: a unifying concept.Brain. 2006 Mar;129(Pt 3):606-16. doi: 10.1093/brain/awl007. Epub 2006 Jan 16. Brain. 2006. PMID: 16415308
-
Mitoxantrone: a review of its use in multiple sclerosis.CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010. CNS Drugs. 2004. PMID: 15089110 Review.
-
Smoking and worsening disability in multiple sclerosis: A meta-analysis.Acta Neurol Scand. 2018 Jul;138(1):62-69. doi: 10.1111/ane.12916. Epub 2018 Mar 15. Acta Neurol Scand. 2018. PMID: 29542102
Cited by
-
Factors associated with relapses in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis.Medicine (Baltimore). 2020 Jul 2;99(27):e20885. doi: 10.1097/MD.0000000000020885. Medicine (Baltimore). 2020. PMID: 32629678 Free PMC article.
-
Immunological Insights into Cigarette Smoking-Induced Cardiovascular Disease Risk.Cells. 2022 Oct 11;11(20):3190. doi: 10.3390/cells11203190. Cells. 2022. PMID: 36291057 Free PMC article. Review.
-
Advances in multiple sclerosis research in 2009.J Neurol. 2010 Sep;257(9):1590-3. doi: 10.1007/s00415-010-5689-y. Epub 2010 Aug 6. J Neurol. 2010. PMID: 20689961 Free PMC article. Review.
-
Lung inflammation stalls Th17-cell migration en route to the central nervous system during the development of experimental autoimmune encephalomyelitis.Int Immunol. 2016 Sep;28(9):463-9. doi: 10.1093/intimm/dxw013. Epub 2016 Mar 17. Int Immunol. 2016. PMID: 26989091 Free PMC article.
-
The Importance of Managing Modifiable Comorbidities in People with Multiple Sclerosis: A Narrative Review.J Pers Med. 2023 Oct 24;13(11):1524. doi: 10.3390/jpm13111524. J Pers Med. 2023. PMID: 38003839 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical